ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Prognostic value of pretreatment peripheral blood biomarkers in patients with head and neck squamous cell carcinoma treated with chemo/bioradiotherapy.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeHematological parameters obtained from a pretreatment peripheral blood lab test, as well as indices calculated from these parameters, are associated with the prognosis of the disease in patients with head and neck squamous cell carcinomas (HNSCC). The aim of this study is to determine which of the parameters or indices would have the best prognostic ability in HNSCC patients treated with chemo-radiotherapy or bio-radiotherapy. METHODS/PATIENTS: Retrospective study of 345 patients with HNSCC treated with chemo/bio-radiotherapy, for whom a pretreatment lab test was available.
resultsOf the parameters and indices analyzed, the one with the best prognostic capacity was the Host-index (H-index), which combines the prognostic capacity of hemoglobin and albumin levels, along with the absolute counts of neutrophils, monocytes, and lymphocytes. This index was available for 309 patients. Based on a recursive partitioning analysis, three groups of patients were defined according to the H-index. Considering as reference the patients with an H-index lower than 1.88 (n = 80, 25.9%), patients with an H-index value between 1.88 and 3.62 (n = 115, 37.2%) had a 2.74 times higher risk of dying due to the tumor (95% CI 1.41-5.30, P = 0.003), and patients with an H-index value greater than 3.62 (n = 114, 36.9%) had a 5.62 times higher risk (95% CI 2.95-10.81, P = 0.0001).
conclusionThe index derived from peripheral blood parameters that showed the best prognostic capacity in patients with head and neck squamous cell carcinoma treated with chemo/bio-radiotherapy was the H-index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.